American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Poster Session C: Renal Cell Cancer; ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Poster Session A: Prostate Cancer. Dr. Moein Moradpour ...

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to ...

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

Though some outcomes were also poorer with an interval less than a year, these were less clinically significant, experts say.

An Australian hospital is examining patient records after a nurse claimed online to have killed Israelis, officials said ...

Stroke experts from UCSF Health presented new research and clinical findings at the annual the American Stroke Association’s International Stroke Conference (ISC25), the world’s premier meeting ...

Ooms' poster at the Association of University Professors of Ophthalmology annual meeting highlighted a study on gray area ...